Incorporation of exogenous lipids modulates insulin signaling in the hepatoma cell line, HepG2.
The lipid content of cultured cells can be experimentally modified by supplementing the culture medium with specific lipids or by the use of phospholipases. In the case of the insulin receptor, these methods have contributed to a better understanding of lipid disorder-related diseases. Previously, our laboratory demonstrated that experimental modification of the cellular lipid composition of an insulin-sensitive rat hepatoma cell line (ZHC) resulted in an alteration in insulin receptor binding and biological action (Bruneau et al., Biochim. Biophys. Acta 928 (1987) 287-296/297-304). In this paper, we have examined the effects of lipid modification in another hepatoma cell line, HepG2. Exogenous linoleic acid (LA, n-6), eicosapentaenoic acid (EPA, n-3) or hemisuccinate of cholesterol (CHS) was added to HepG2 cells, to create a cellular model in which membrane composition was modified. In this model, we have shown that: (1) lipids were incorporated in treated HepG2 cells, but redistributed differently when compared to treated ZHC cells; (2) that insulin signaling events, such as insulin receptor autophosphorylation and the phosphorylation of the major insulin receptor substrate (IRS-1) were altered in response to the addition of membrane lipids or cholesterol derived components; and (3) different lipids affected insulin receptor signaling differently. We have also shown that the loss of insulin receptor autophosphorylation in CHS-treated cells can be correlated with a decreased sensitivity to insulin. Overall, the results suggest that the lipid environment of the insulin receptor may play an important role in insulin signal transduction.
Meuillet
E J
EJ
Children's Memorial Hospital, Pediatric Brain Tumor Research Program, CMIER Building, 2300 Children's Plaza, M/C 226, Chicago, IL 60614, USA. e-meuillet@nwu.edu
Leray
V
V
Hubert
P
P
Leray
C
C
Cremel
G
G
D000818:Animals; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002784:Cholesterol / Q000032:analysis; D002788:Cholesterol Esters / Q000494:pharmacology; D015118:Eicosapentaenoic Acid / Q000494:pharmacology; D005227:Fatty Acids / Q000032:analysis; D019787:Linoleic Acid / Q000494:pharmacology; D008055:Lipids / Q000302:isolation & purification / Q000494:pharmacology*; D008560:Membrane Fluidity / Q000187:drug effects; D051381:Rats; D011972:Receptor, Insulin / Q000378:metabolism*; D015398:Signal Transduction; D014280:Triglycerides / Q000032:analysis; D014407:Tumor Cells, Cultured
D002788:Cholesterol Esters; D005227:Fatty Acids; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D019787:Linoleic Acid; D015118:Eicosapentaenoic Acid; D011972:Receptor, Insulin; C013440:cholesteryl succinate